The Prostate Health Index is a Food and Drug Administration-approved blood test combining total, free, and [-2]pro prostate-specific antigen with greater specificity than free and total prostate-specific antigen for clinically significant prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This article reviews the evidence on the performance of the Prostate Health Index to predict prostate biopsy outcome, its incorporation into multivariable risk-assessment tools, and its ability to predict prognosis after conservative management or prostate cancer treatment.
The Urologic clinics of North America. 2016 Mar [Epub]
Abbey Lepor, William J Catalona, Stacy Loeb
Department of Urology, New York University, New York, NY, USA. , Department of Urology, Northwestern Feinberg School of Medicine, 675 North St. Clair Street, Galter Suite 20-150, Chicago, Illinois 60611, USA. , Department of Urology, New York University, New York, NY, USA; Department of Population Health, Laura and Isaac Perlmutter Cancer Center, New York University, New York, NY, USA.